Vaccines

Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)

Retrieved on: 
Tuesday, October 13, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Medical research, Medicine, Articles, Branches of biology, Vaccines, COVID-19 vaccine, Moderna, Vaccine, Messenger RNA, Draft:Treatments & Vaccines for COVID-19, Operation Warp Speed, Moderna’s Prophylactic Vaccines Modality, Moderna

Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Companys vaccine candidate against COVID-19.

Key Points: 
  • Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Companys vaccine candidate against COVID-19.
  • Health Canada will not make a decision to authorize any vaccine being considered under rolling review until it has received all necessary evidence to support its safety and efficacy.
  • Following the authorization of any vaccine submission, Health Canada will publish the evidence used in making its decision for transparency.
  • Moderna remains on track to be able to deliver up to 56 million doses of its COVID-19 vaccine to help protect Canadians beginning in 2021.

Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine

Retrieved on: 
Tuesday, October 13, 2020
Medicine, Medical specialties, Health, Vaccination, Medical research, Vaccines, Vaxart, Virology, Reactogenicity, Vaccine, VXA, Severe acute respiratory syndrome

We are eager to explore the clinical profile of VXA-CoV2-1 for effective protection against SARS-CoV-2 infection and transmission in healthy adults.

Key Points: 
  • We are eager to explore the clinical profile of VXA-CoV2-1 for effective protection against SARS-CoV-2 infection and transmission in healthy adults.
  • Enrollment is expected to be completed by early November 2020, with participants receiving the low or high dose of the VXA-CoV2-1 oral tablet at days 1 and 29.
  • Safety, reactogenicity and immunogenicity assessments will be performed at set times during the active phase.
  • We are very excited about our oral tablet vaccine entering the clinic because we believe that the COVID-19 pandemic needs an oral alternative to injectable vaccines, said Andrei Floroiu, chief executive officer ofVaxart.

Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure

Retrieved on: 
Tuesday, October 13, 2020
Novavax, Medical specialties, Health care, Health, Vaccine, Medical research, Vaccines

GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, J.D./M.B.A., to Executive Vice President and the newly-created role of NanoFlu General Manager.

Key Points: 
  • GAITHERSBURG, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, J.D./M.B.A., to Executive Vice President and the newly-created role of NanoFlu General Manager.
  • I have full confidence in Rip and our team, which has brought NanoFlu from inception through successful Phase 3 testing.
  • In his new role, he will lead a team that will work closely with the broader Novavax team to obtain licensure for NanoFlu from FDA and other global authorities, as well as evaluate the development of a pentavalent NanoFlu/NVX-CoV2373 vaccine.
  • The new NanoFlu leadership team includes several Novavax veterans who led the successful development of the vaccine through completion of its successful pivotal Phase 3 clinical trial.

Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

Retrieved on: 
Tuesday, October 13, 2020
Medical specialties, Medicine, Health, Medical research, COVID-19 vaccine, Vaccines, Vaccine, Immunologic adjuvant

The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October.

Key Points: 
  • The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October.
  • The grant received by MVC was earmarked by the Taiwan government for purposes of research and development of a locally produced COVID-19 vaccine.
  • Dynavax is also further developing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships.
  • This press release contains "forward-looking" statements, including statements regarding the potential to develop a COVID-19 vaccine containing CpG 1018.

Hepatitis B Vaccines Market will Showcase Neutral Impact During 2020-2024 | High Prevalence of Hepatitis B Globally to Boost Market Growth | Technavio

Retrieved on: 
Tuesday, October 13, 2020
Health, Infectious diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Health, RTT, Vaccination, Vaccines, Hepatitis B, Vaccine, Virology, Hepatitis

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20201012005794/en/
    Technavio has announced its latest market research report titled Global Hepatitis B Vaccines Market 2020-2024 (Graphic: Business Wire)
    Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • High prevalence of hepatitis B globally has been instrumental in driving the growth of the market.
  • Download a Free Sample Report on COVID-19 Impacts
    Hepatitis B Vaccines Market 2020-2024: Segmentation
    Hepatitis B Vaccines Market is segmented as below:

2020 Zika Virus Market Spotlight: Inovio Leads Industry Sponsors with Four Clinical Trials, Followed by GeneOne, Moderna, and Sanofi

Retrieved on: 
Monday, October 12, 2020
Zika virus, Health, Vaccines, Medicine, Companies, Flaviviruses, Medical research, Inovio Pharmaceuticals, Zika fever, Sanofi, Zika virus vaccine, Zika virus epidemic

This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.

Key Points: 
  • This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.
  • The Zika virus was first reported in continental South America in Brazil in May 2015.
  • All clinical trials for Zika virus have been in either Phase I or Phase II, with no Phase III trials to date.
  • Inovio leads industry sponsors with four clinical trials for Zika virus, followed by GeneOne, Moderna, and Sanofi.

AuraVax Therapeutics Enters into Exclusive License Option Agreement with the University of Houston for Intranasal Vaccine Platform

Retrieved on: 
Monday, October 12, 2020
Medicine, Health, Medical research, Medical specialties, Vaccination, Vaccine, Virology, Vaccines, Specialty drugs, COVID-19 vaccine

"We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine platform to address a multitude of respiratory viruses, starting with COVID-19.

Key Points: 
  • "We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine platform to address a multitude of respiratory viruses, starting with COVID-19.
  • The partnership has my wholehearted support," said Amr Elnashai, University of Houston vice president for research and technology transfer.
  • AuraVax Therapeutics Inc.("AuraVax") is a privately held biotechnology company developing a proprietary and differentiated platform of vaccines against various respiratory viruses including COVID-19.
  • Its next-generation vaccine platform combines the potential of in-home administration with the ability to deliver complete immunity.

AHF Says US Taxpayers Co-own Moderna’s COVID-19 VAX Patent

Retrieved on: 
Thursday, October 8, 2020
Biotechnology, AIDS, White House, Federal Government, Health, General Health, Healthcare reform, Public policy, Pharmaceutical, Infectious diseases, Congressional News, Views, Public policy, Government, Medical research, Health, Medicine, Articles, AIDS Healthcare Foundation, Vaccines, COVID-19 vaccine, Moderna, AHF, Biomedical Advanced Research and Development Authority, Vaccine

(read Moderna statement )

Key Points: 
  • (read Moderna statement )
    Moderna reportedly received over $1.4 billion from the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services ( BARDA ) to produce 100 million doses of its COVID-19 vaccine.
  • AHF agrees with many activists that as the angel investor in the vaccine research, the U.S. taxpayer co-owns the patent, said John Hassell, national director of advocacy for AHF.
  • AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.4 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

Patient Safety Authority Launches Statewide Campaign "Knock out the Flu, PA"

Retrieved on: 
Thursday, October 8, 2020
RTT, Influenza vaccine, Vaccines, Medical specialties, Influenza A virus subtype H1N1, Influenza, Health care, Health

HARRISBURG, Pa., Oct. 8, 2020 /PRNewswire/ --The Patient Safety Authority (PSA) has kicked off Knock out the Flu, PAa comprehensive campaign that urges Pennsylvanians to get a flu shot.

Key Points: 
  • HARRISBURG, Pa., Oct. 8, 2020 /PRNewswire/ --The Patient Safety Authority (PSA) has kicked off Knock out the Flu, PAa comprehensive campaign that urges Pennsylvanians to get a flu shot.
  • A social media campaign featuring influencers and everyday citizens is also underway.
  • All Pennsylvanians are encouraged to join the flu shot challenge by getting vaccinated and posting a photo with the hashtag #KnockOutTheFluPA.
  • "Getting a flu shot also makes it less likely that you'll give the virus to someone else.

Americans Split Over Safety of Vaccines; 36% Say They Won't Take COVID-19 Vaccine When Made Available

Retrieved on: 
Thursday, October 8, 2020
Medicine, Medical specialties, Vaccines, Health, Vaccination, Medical research, COVID-19 vaccine, Vaccine, HIV/AIDS, Gam-COVID-Vac, Swine flu pandemic vaccine

While a slight majority (51%) of American likely voters say they will take the COVID-19 vaccine when available, 36% say no, leaving 14% unsure.In other words, exactly half of the population are unwilling and hesitant about getting the COVID-19 vaccine.

Key Points: 
  • While a slight majority (51%) of American likely voters say they will take the COVID-19 vaccine when available, 36% say no, leaving 14% unsure.In other words, exactly half of the population are unwilling and hesitant about getting the COVID-19 vaccine.
  • When asked about reasons for not getting the vaccine, the most common answer (59%) is "afraid of vaccine side effects ."
  • A follow-up question asked respondents how safe they believe the COVID-19 vaccine would be when made available.
  • The most common answer among the nearly three in ten Americans who believe the vaccine will be unsafe, cite "rushed/needs more testing" as a concern .